Gastrointestinal-Pancreas (GI-P) Pathology Research Group

Per Arne Andresen

Our research group studies the genetics/gene expression of pancreatic, liver, and colorectal cancers with the aim of identifying biomarkers for early detection and prognosis. We utilize benign and malignant human tumor tissues and cancer cell culture models to investigate protein signaling pathways involved in cellular growth, senescence, chemotherapy response, and tumor-stroma interactions.

Research project groups

There are 3 project groups described as follows:

1. Neoadjuvant treatment for pancreatic cancer: towards improved patient selection and assessment of treatment effect 
Project group leader is Caroline Verbeke.  Visit her UiO home page

  • Characterization of residual, i.e., resistant tumor by broad morphological and molecular analysis of both the cancer cell population and tumor stroma
  • Analysis of novel markers predictive of distant metastasis for improved patient selection for neoadjuvant treatment

2. Molecular Mechanisms of Drug Resistance
Project group leader is Paula M De Angelis.  

  • Characterization of DNA damage response and DNA repair pathways in colorectal cancer and ulcerative colitis
  • Identification of clinically-useful biomarkers of drug response

3. Molecular and Clinical Aspects of Colorectal and Liver Tumors
Project group leader: Per Arne Andresen

  • Colorectal polyposis syndromes; APC- and MUTYH genotype-phenotype correlations in Norwegian families
  • Mechanisms involved in colorectal polyp persistence and neoplastic transition. Studies on material collected from the prospectively designed NORCCAP (Norwegian Colorectal Cancer Prevention) screening study 
  • Primary and secondary hepatic tumors and their genomic alterations in inflammatory and non-inflammatory liver diseases (coordinated by prof. em. Eide)
  • Primary sclerosing cholangitis and related liver-diseases. Pathogenesis and predisposition to malignancy (coordinated by prof. em. Eide in collaboration with the research group of Professor Tom Hemming Karlsen).